U.S. markets open in 5 hours 47 minutes
  • S&P Futures

    3,916.50
    +12.75 (+0.33%)
     
  • Dow Futures

    31,535.00
    +114.00 (+0.36%)
     
  • Nasdaq Futures

    12,078.00
    +37.50 (+0.31%)
     
  • Russell 2000 Futures

    1,778.90
    +9.10 (+0.51%)
     
  • Crude Oil

    111.06
    +1.49 (+1.36%)
     
  • Gold

    1,827.30
    +2.50 (+0.14%)
     
  • Silver

    21.25
    +0.08 (+0.36%)
     
  • EUR/USD

    1.0591
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    27.09
    -0.14 (-0.51%)
     
  • GBP/USD

    1.2262
    -0.0008 (-0.06%)
     
  • USD/JPY

    135.7920
    +0.3460 (+0.26%)
     
  • BTC-USD

    20,884.28
    -462.91 (-2.17%)
     
  • CMC Crypto 200

    455.61
    -6.19 (-1.34%)
     
  • FTSE 100

    7,315.72
    +57.40 (+0.79%)
     
  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

Affimed to Present at Jefferies Virtual Cell Therapy Summit

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.


Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the company’s management will present at the Jefferies Virtual Cell Therapy Conference on Tuesday, October 6 at 8:00 a.m. Eastern Time.

A live webcast of the presentation can be accessed under the “Investors” section of Affimed’s website at https://www.affimed.com/investors/webcasts_cp/ and will be available for 30 days following the event.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30+ relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Affimed Investor Contact

Alexander Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: (917) 436-8102